Developer docs
API playgroundTry for free, no card

Search company profiles

Tenax Therapeutics

Full company profile

uuid0004fyc

Namestring
Tenax Therapeutics
Legal namestring
Tenax Therapeutics, Inc.
Websiteurl
tenaxthera.com
Company typeenum
Public
Founded yearint
1967
Descriptiontext

Tenax Therapeutics is a Phase 3 development-stage specialty pharmaceutical company headquartered in Chapel Hill, North Carolina, publicly traded on NASDAQ under the ticker TENX. The company is singularly focused on developing treatments for cardiopulmonary diseases, with its lead and only clinical asset being TNX-103, an oral formulation of levosimendan, being advanced for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) — a debilitating, often fatal condition affecting an estimated 2.1 million Americans for which there are currently no approved treatments. TNX-103 works through a novel mechanism: as a first-in-class potassium-ATP channel activator and calcium sensitizer, it produces a potent and specific dilatory effect on the splanchnic (abdominal) venous circulation, thereby reducing elevated venous blood volume and lowering pulmonary capillary wedge pressure (PCWP), the hemodynamic hallmark of PH-HFpEF. Levosimendan itself is authorized in its intravenous form in 60 countries for acute decompensated heart failure (ADHF), providing Tenax with a substantial pre-existing safety database spanning more than two decades of clinical use that materially derisks the Phase 3 program.

The company's clinical program consists of two Phase 3 trials: the LEVEL trial, a 12-week randomized study conducted in the U.S. and Canada, which completed randomization of 230 patients in March 2026 with topline data expected in Q3 2026; and the LEVEL-2 trial, a 26-week global Phase 3 study initiated in 2026 with enrollment targeted to complete by year-end 2027 and topline data anticipated in H2 2028. TNX-103 is reported as the only drug candidate to demonstrate exercise improvement (via six-minute walk test) and profound improvements in exercise hemodynamics in PH-HFpEF patients, and the company holds a U.S. patent covering levosimendan's use in this indication.

As a pre-commercial clinical-stage company, Tenax generates no product revenue and its business model is entirely reliant on equity capital markets to fund R&D and operating expenses. The company has no pricing model, no distribution channels, and no commercial customers; it has explicitly disclosed no commercial revenue. Operations are funded through a series of equity financings including an $8M PIPE (May 2022), a $15.6M public offering (February 2023), a $9.04M public offering (February 2024), a $100M oversubscribed private placement led by BVF Partners LP (August 2024), and a $25M private placement with RTW Investments (March 2025). The company reported a $52.6M net loss for 2025, with stated cash runway expected to fund operations through 2027. Leadership is concentrated among experienced pharmaceutical executives, including CEO Chris Giordano (formerly President of IQVIA Biotech), CMO Dr. Stuart Rich (Professor Emeritus of Medicine at Northwestern), and recent C-suite additions Thomas Staab (CFO, effective May 2026) and Timothy Healey (CCO, May 2026) signaling pre-launch commercial buildout.

Short descriptiontext

Tenax Therapeutics is a Phase 3 clinical-stage pharmaceutical company developing TNX-103, an oral formulation of levosimendan, as a potential first treatment for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), addressing roughly 2.1 million U.S. patients with no approved therapies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChapel Hill, United States
HQ citystring
Chapel Hill
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pulmonary hypertension therapeutics, cardiopulmonary drug development, heart failure treatments, clinical stage biopharmaceuticals, potassium channel activators
Industry2 codes
PRIMARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cardiopulmonary Specialty Pharmaceuticals
Social media profiles2 records
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tenax Therapeutics is developing TNX-103, an oral formulation of levosimendan, as a first-in-class treatment for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The drug works as a potassium-ATP channel activator and calcium sensitizer, targeting the splanchnic venous circulation to reduce elevated pulmonary capillary wedge pressure. The company is currently executing a Phase 3 registrational program consisting of the LEVEL and LEVEL-2 clinical trials, with no products approved or commercialized to date.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Only drug to show exercise improvement (6-minute walk test) in PH-HFpEF patients with profound improvements in exercise hemodynamics
+2 more records
Product overview1 text field

Tenax Therapeutics is a Phase 3 development-stage pharmaceutical company with a single focused product candidate: TNX-103, an oral formulation of levosimendan. The company is executing a derisked Phase 3 registrational program consisting of the LEVEL trial (12-week, randomized, Canada & U.S.) and the subsequent LEVEL-2 trial (26-week global study). The product candidate addresses a significant unmet medical need for PH-HFpEF, for which there are no approved treatments. The drug candidate's development is supported by established safety data from over two decades of clinical use of intravenous levosimendan in acute heart failure settings.

Product and service1 record
1TNX-103 (Oral Levosimendan)
CategoryCardiopulmonary Specialty Pharmaceuticals
Description

TNX-103 is an oral formulation of levosimendan, a first-in-class potassium-ATP channel activator and calcium sensitizer, being developed for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). It works by targeting the splanchnic venous circulation to lower elevated pulmonary capillary wedge pressure. Levosimendan is currently authorized for use in 60 countries in its intravenous form for acute decompensated heart failure. The product is intended for PH-HFpEF patients — a population of over 2.1 million in the United States with no approved treatment options.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage rare disease biotech with cardiovascular programs (e.g., acoramidis for transthyretin amyloid cardiomyopathy); comparable as a similarly structured late-stage biotech with single-asset concentration and capital-intensive development model.

TypeBroad incumbent
Description

Major cardiovascular pharma with sildenafil (Revatio) approved for PAH and broad cardiopulmonary R&D; comparable as a potential strategic acquirer for TNX-103 given large-pharma infrastructure in cardiovascular drug commercialization.

TypeEmerging player
Description

Small-cap clinical-stage company focused on cardiovascular and metabolic diseases; comparable as a similarly-sized peer pursuing novel mechanisms in cardiopulmonary indications with similar resource constraints.

TypeDirect peer
Description

Late-stage clinical company developing inhaled imatinib for pulmonary arterial hypertension (PAH), a direct competitor targeting the same PH disease space with a different mechanism; both companies are pursuing first-in-class oral/inhaled therapies for underserved PH indications.

TypeDirect peer
Description

Commercial-stage PH company (YUTREPIA, inhaled treprostinil) targeting pulmonary hypertension and pulmonary-interstitial lung disease. Comparable business model focused on reformulated/improved delivery of established PH therapies.

TypeBroad incumbent
Description

Markets riociguat (Adempas), the only approved therapy for chronic thromboembolic pulmonary hypertension (CTEPH), and has broad cardiovascular/pulmonary franchise. Comparable given established PH commercial presence and large-pharma cardiovascular R&D.

TypeBroad incumbent
Description

Commercial-stage respiratory biopharma with ARIKAYCE for lung infections and a growing pipeline in serious lung diseases including PH. Comparable given its focus on inhaled therapies for cardiopulmonary indications and larger commercial reach.

TypeEmerging player
Description

Clinical-stage biopharma developing seralutinib (inhaled PDGFR inhibitor) for PAH — directly comparable late-stage pulmonary hypertension program with novel mechanism targeting similar patient population.

TypeDirect peer
Description

Established pulmonary hypertension leader with approved PH therapies (Remodulin, Tyvaso, Orenitram) including inhaled treprostinil for PH-ILD. Most directly comparable to Tenax given overlapping PH indication, and Tenax CMO Stuart Rich previously served as part-time CMO of United Therapeutics.

TypeBroad incumbent
Description

Acquired Acceleron Pharma in 2021 for sotatercept (Winrevair), now approved for PAH — the most significant new PH therapy launch in years and a key benchmark for the commercial potential of PH-HFpEF therapies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tenax Therapeutics

Cardiopulmonary Specialty Pharmaceuticalstenaxthera.com

Tenax Therapeutics is a Phase 3 clinical-stage pharmaceutical company developing TNX-103, an oral formulation of levosimendan, as a potential first treatment for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), addressing roughly 2.1 million U.S. patients with no approved therapies.

What Tenax Therapeutics does

Tenax Therapeutics is a Phase 3 development-stage specialty pharmaceutical company headquartered in Chapel Hill, North Carolina, publicly traded on NASDAQ under the ticker TENX. The company is singularly focused on developing treatments for cardiopulmonary diseases, with its lead and only clinical asset being TNX-103, an oral formulation of levosimendan, being advanced for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) — a debilitating, often fatal condition affecting an estimated 2.1 million Americans for which there are currently no approved treatments. TNX-103 works through a novel mechanism: as a first-in-class potassium-ATP channel activator and calcium sensitizer, it produces a potent and specific dilatory effect on the splanchnic (abdominal) venous circulation, thereby reducing elevated venous blood volume and lowering pulmonary capillary wedge pressure (PCWP), the hemodynamic hallmark of PH-HFpEF. Levosimendan itself is authorized in its intravenous form in 60 countries for acute decompensated heart failure (ADHF), providing Tenax with a substantial pre-existing safety database spanning more than two decades of clinical use that materially derisks the Phase 3 program.

The company's clinical program consists of two Phase 3 trials: the LEVEL trial, a 12-week randomized study conducted in the U.S. and Canada, which completed randomization of 230 patients in March 2026 with topline data expected in Q3 2026; and the LEVEL-2 trial, a 26-week global Phase 3 study initiated in 2026 with enrollment targeted to complete by year-end 2027 and topline data anticipated in H2 2028. TNX-103 is reported as the only drug candidate to demonstrate exercise improvement (via six-minute walk test) and profound improvements in exercise hemodynamics in PH-HFpEF patients, and the company holds a U.S. patent covering levosimendan's use in this indication.

As a pre-commercial clinical-stage company, Tenax generates no product revenue and its business model is entirely reliant on equity capital markets to fund R&D and operating expenses. The company has no pricing model, no distribution channels, and no commercial customers; it has explicitly disclosed no commercial revenue. Operations are funded through a series of equity financings including an $8M PIPE (May 2022), a $15.6M public offering (February 2023), a $9.04M public offering (February 2024), a $100M oversubscribed private placement led by BVF Partners LP (August 2024), and a $25M private placement with RTW Investments (March 2025). The company reported a $52.6M net loss for 2025, with stated cash runway expected to fund operations through 2027. Leadership is concentrated among experienced pharmaceutical executives, including CEO Chris Giordano (formerly President of IQVIA Biotech), CMO Dr. Stuart Rich (Professor Emeritus of Medicine at Northwestern), and recent C-suite additions Thomas Staab (CFO, effective May 2026) and Timothy Healey (CCO, May 2026) signaling pre-launch commercial buildout.

Tenax Therapeutics firmographics

Firmographics
Name
Tenax Therapeutics
Legal name
Tenax Therapeutics, Inc.
Website
https://tenaxthera.com
Company type
Public
Founded year
1967
Operating status
Operating
Headcount range
11–50 employees
Short description
Tenax Therapeutics is a Phase 3 clinical-stage pharmaceutical company developing TNX-103, an oral formulation of levosimendan, as a potential first treatment for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), addressing roughly 2.1 million U.S. patients with no approved therapies.
Ownership category
akta.pro rank

Tenax Therapeutics industry classification

Industry
Product category
Cardiopulmonary Specialty Pharmaceuticals
NAICS
Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Pulmonary hypertension therapeutics
  • Cardiopulmonary drug development
  • Heart failure treatments
  • Clinical stage biopharmaceuticals
  • Potassium channel activators

Where Tenax Therapeutics is headquartered

Location

Headquarters

HQ city
Chapel Hill
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Tenax Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Marketing channels3 records

Tenax Therapeutics product offering

Product offering

Core offering

Tenax Therapeutics is developing TNX-103, an oral formulation of levosimendan, as a first-in-class treatment for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The drug works as a potassium-ATP channel activator and calcium sensitizer, targeting the splanchnic venous circulation to reduce elevated pulmonary capillary wedge pressure. The company is currently executing a Phase 3 registrational program consisting of the LEVEL and LEVEL-2 clinical trials, with no products approved or commercialized to date.

Product overview

Tenax Therapeutics is a Phase 3 development-stage pharmaceutical company with a single focused product candidate: TNX-103, an oral formulation of levosimendan. The company is executing a derisked Phase 3 registrational program consisting of the LEVEL trial (12-week, randomized, Canada & U.S.) and the subsequent LEVEL-2 trial (26-week global study). The product candidate addresses a significant unmet medical need for PH-HFpEF, for which there are no approved treatments. The drug candidate's development is supported by established safety data from over two decades of clinical use of intravenous levosimendan in acute heart failure settings.

Differentiator

Problem solved

Functional benefit

Products and services

  • TNX-103 (Oral Levosimendan) TNX-103 is an oral formulation of levosimendan, a first-in-class potassium-ATP channel activator and calcium sensitizer, being developed for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). It works by targeting the splanchnic venous circulation to lower elevated pulmonary capillary wedge pressure. Levosimendan is currently authorized for use in 60 countries in its intravenous form for acute decompensated heart failure. The product is intended for PH-HFpEF patients — a population of over 2.1 million in the United States with no approved treatment options.

Quantifiable outcome

  • Only drug to show exercise improvement (6-minute walk test) in PH-HFpEF patients with profound improvements in exercise hemodynamics
  • +2 more outcomes

Companies that use Tenax Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Tenax Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Tenax Therapeutics partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Tenax Therapeutics competitors and assessment

Company assessment

Emerging players

  • BridgeBio Pharma: Clinical-stage rare disease biotech with cardiovascular programs (e.g., acoramidis for transthyretin amyloid cardiomyopathy); comparable as a similarly structured late-stage biotech with single-asset concentration and capital-intensive development model.
  • Lexicon Pharmaceuticals: Small-cap clinical-stage company focused on cardiovascular and metabolic diseases; comparable as a similarly-sized peer pursuing novel mechanisms in cardiopulmonary indications with similar resource constraints.
  • Gossamer Bio: Clinical-stage biopharma developing seralutinib (inhaled PDGFR inhibitor) for PAH — directly comparable late-stage pulmonary hypertension program with novel mechanism targeting similar patient population.

Broad incumbents

  • Pfizer: Major cardiovascular pharma with sildenafil (Revatio) approved for PAH and broad cardiopulmonary R&D; comparable as a potential strategic acquirer for TNX-103 given large-pharma infrastructure in cardiovascular drug commercialization.
  • Bayer AG: Markets riociguat (Adempas), the only approved therapy for chronic thromboembolic pulmonary hypertension (CTEPH), and has broad cardiovascular/pulmonary franchise. Comparable given established PH commercial presence and large-pharma cardiovascular R&D.
  • Insmed: Commercial-stage respiratory biopharma with ARIKAYCE for lung infections and a growing pipeline in serious lung diseases including PH. Comparable given its focus on inhaled therapies for cardiopulmonary indications and larger commercial reach.
  • Merck & Co. (Acceleron acquisition): Acquired Acceleron Pharma in 2021 for sotatercept (Winrevair), now approved for PAH — the most significant new PH therapy launch in years and a key benchmark for the commercial potential of PH-HFpEF therapies.

Direct peers

  • Aerovate Therapeutics: Late-stage clinical company developing inhaled imatinib for pulmonary arterial hypertension (PAH), a direct competitor targeting the same PH disease space with a different mechanism; both companies are pursuing first-in-class oral/inhaled therapies for underserved PH indications.
  • Liquidia Corporation: Commercial-stage PH company (YUTREPIA, inhaled treprostinil) targeting pulmonary hypertension and pulmonary-interstitial lung disease. Comparable business model focused on reformulated/improved delivery of established PH therapies.
  • United Therapeutics: Established pulmonary hypertension leader with approved PH therapies (Remodulin, Tyvaso, Orenitram) including inhaled treprostinil for PH-ILD. Most directly comparable to Tenax given overlapping PH indication, and Tenax CMO Stuart Rich previously served as part-time CMO of United Therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Tenax Therapeutics social profiles

Digital presence

Tenax Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tenax Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

Tenax Therapeutics funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tenax Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tenax Therapeutics

What does Tenax Therapeutics do?

Tenax Therapeutics is developing TNX-103, an oral formulation of levosimendan, as a first-in-class treatment for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The drug works as a potassium-ATP channel activator and calcium sensitizer, targeting the splanchnic venous circulation to reduce elevated pulmonary capillary wedge pressure. The company is currently executing a Phase 3 registrational program consisting of the LEVEL and LEVEL-2 clinical trials, with no products approved or commercialized to date.

Is Tenax Therapeutics a public or private company?

Tenax Therapeutics is a public company. It is classified as public and is currently operating.

When was Tenax Therapeutics founded?

Tenax Therapeutics was founded in 1967. It employs 11 to 50 people.

Where is Tenax Therapeutics based?

Tenax Therapeutics is headquartered in Chapel Hill, United States, in the North America region.

Who are Tenax Therapeutics's main competitors?

Emerging players on record are BridgeBio Pharma, Lexicon Pharmaceuticals and Gossamer Bio. Broad incumbents are Pfizer, Bayer AG, Insmed and Merck & Co. (Acceleron acquisition). Direct peers are Aerovate Therapeutics, Liquidia Corporation and United Therapeutics.

Does Tenax Therapeutics have an API?

No public API is recorded for Tenax Therapeutics.

What industry is Tenax Therapeutics in?

Tenax Therapeutics's product category is Cardiopulmonary Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAG, Pulmonary Hypertension & Rare Pulmonary Disease Therapies, with a secondary code of HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies. Its NAICS code is 5417 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireDEADLINE ALERT for Tenax Therapeutics, Inc. (TENX), Everest Group, Ltd. (EG), and Lululemon Athletica, Inc (LULU): The Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsThe Law Offices of Howard G. Smith announced class action lawsuits against Tenax Therapeutics, Everest Group, and Lululemon Athletica, with lead plaintiff deadlines of December 28, 2026 for the first two and January 4, 2027 for Lululemon. The complaints allege false or misleading statements regarding product effectiveness, casualty risk exposure, and deteriorating store traffic.GlobeNewswireDEADLINE ALERT for UP Fintech Holding Limited (TIGR), Tenax Therapeutics, Inc. (TENX), Everest Group, Ltd. (EG), and Yiren Digital Ltd. (YRD): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class ActionsThe Law Offices of Frank R. Cruz reminds investors of lead plaintiff deadlines for securities class actions against UP Fintech, Tenax Therapeutics, Everest Group, and Yiren Digital. All deadlines are December 28, 2026, with complaints alleging false statements about risks and financial distress. No class has been certified yet.NewsfileTENAX THERAPEUTICS, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs Tenax Therapeutics, Inc. (TENX) Investors of a Securities Fraud LawsuitBerger Montague filed a securities fraud class action against Tenax Therapeutics, alleging it overstated the prospects of its lead drug candidate TNX-103 for pulmonary hypertension. The complaint cites a Phase 3 trial failure and an 89.77% stock drop to $1.38 per share on August 10, 2026. Investors have until December 28, 2026, to seek lead plaintiff status.AktienTENAX THERAPEUTICS, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs Tenax Therapeutics, Inc. (TENX) Investors of a Securities Fraud LawsuitBerger Montague filed a securities fraud class action against Tenax Therapeutics, alleging overstated prospects for its drug TNX-103. The complaint cites the Phase 3 LEVEL trial results, which showed the drug failed to meet primary endpoints, causing a stock drop of 89.77% to $1.38. Investors have until December 28, 2026, to seek lead plaintiff status.AktienSHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (TENX) - Investors Who Suffered Losses Are Encouraged to Contact the FirmBronstein Gewirtz & Grossman filed a securities class action against Tenax Therapeutics, alleging false and misleading statements about its lead clinical program TNX-103. Investors who bought TENX securities between November 13, 2023 and August 7, 2026 may be eligible for recovery, with a lead plaintiff deadline of December 28, 2026.AktienFaruqi & Faruqi, LLP Urges Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors to Seek Counsel Before the December 28, 2026 Lead Plaintiff Deadline in the Securities Class ActionFaruqi & Faruqi, LLP reminds Tenax Therapeutics investors of the December 28, 2026 lead plaintiff deadline in a federal securities class action. The lawsuit alleges false statements about TNX-103's effectiveness, and Tenax shares fell about 89.77% on August 10, 2026.